Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of omalizumab up to 48 weeks in adult
patients with moderate to severe bronchial asthma.
THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES